Incyte

#News: Incyte receives approval of a treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) from the @EU_Commission. Read to learn more. bit.ly/4lfcthD

Read our press release for Incyte’s Q4 and FY2025 financial results and updates on our key clinical programs. bit.ly/4apRJ1K

At the @JPMorgan Healthcare Conference this week, we shared how we’re transforming into a high-growth company. Download the presentation and listen to the recording here. #JPM2026 bit.ly/4sOJ9SA

Incyte to present updates on our business, pipeline progress and upcoming milestones at the 44th Annual @jpmorgan Healthcare Conference. #JPM2026 bit.ly/49uy2Fx

We’ve announced positive topline results from the Phase 3 frontMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Read our press release to learn more. bit.ly/3Ng7CQd

Today, Japan’s Ministry of Health, Labour and Welfare (MHLW) approved our treatment for certain patients with squamous cell carcinoma of the anal canal (SCAC). Learn more. bit.ly/4qlfYEo

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved our new targeted immunotherapy combination for adults with relapsed or refractory follicular lymphoma (FL). Learn more. bit.ly/4p9PJQy

We are committed to driving innovation in hematology, with research spanning multiple types of cancer, including follicular lymphoma (FL). Learn more about FL. bit.ly/3YDkvpO

#News: The @EU_Commission approved a new therapy for certain adults with relapsed or refractory follicular lymphoma (FL). Read our press release to learn more. bit.ly/4pM4Lgm

#ASH25 brought together the brightest minds in hematology to share breakthroughs, connect with peers and advance patient care. Thank you @ASH_hematology for fostering innovation and collaboration that drives the field forward!

New data evaluating our novel first-in-class mutCALR-targeted monoclonal antibody in patients with essential thrombocythemia (ET) at #ASH25. @ASH_hematology bit.ly/3XJMHXT

Discover insights into our mutant calreticulin (mutCALR)-targeted monoclonal antibody for patients with essential thrombocythemia (ET). bit.ly/3XJMHXT

Today, we presented updated data for patients with essential thrombocythemia (ET) at #ASH25. Learn more by reading our press release. @ASH_hematology bit.ly/3XJMHXT

Check out our booth at #ASH25 where we are connecting with the hematology community!

What is mutCALR and what does it do? Learn more from Pablo J. Cagnoni, M.D., President and Head of Research & Development at Incyte, about the research behind our mutCALR-targeted monoclonal antibody. #ASH25 bit.ly/4iNHjg2

We’re at #ASH25! Follow along for the latest updates from #TeamIncyte, live from Orlando.

At Incyte we’re committed to transforming the treatment of blood cancers, especially for patients with myeloproliferative neoplasms (MPNs). Hear from our CEO, Bill Meury, as he discusses the myelofibrosis (MF) data presented at #ASH25. Learn more. @ASH_hematology bit.ly/4pPvhoz

Learn more about the data we presented at #ASH25 evaluating our mutCALR-targeted monoclonal antibody in patients with myelofibrosis (MF). @ASH_hematology bit.ly/3Mueedk

We’re proud to share that the @FDA has granted Breakthrough Therapy designation to our first-in-class mutCALR-targeted monoclonal antibody. Read more: bit.ly/4poHktr

Today, we announced new data evaluating our mutCALR-targeted monoclonal antibody in patients with myelofibrosis (MF) at #ASH25. Read the press release to learn more. @ASH_hematology bit.ly/3Mueedk